Abstract:Various vaccine strategies have been proposed in response to the global COVID-19 pandemic, each with unique strategies for eliciting immune responses. Here, we developed nanoparticle vaccines by covalently conjugating the self-assembled 24-mer ferritin to the receptor binding domain (RBD) and/or heptad repeat (HR) subunits of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spike (S) protein. Compared to monomer vaccines, nanoparticle vaccines elicited more robust neutralizing antibodies and cellular immune responses. RBD and RBD-HR nanoparticle vaccinated hACE2 transgenic mice vaccinated with RBD and/or RBD-HR nanoparticles exhibited reduced viral load in the lungs after SARS-CoV-2 challenge. RBD-HR nanoparticle vaccines also promoted neutralizing antibodies and cellular immune responses against other coronaviruses. The nanoparticle vaccination of rhesus macaques induced neutralizing antibodies, and T and B cell responses prior to boost immunization; these responses persisted for more than three months. RBD- and HR-based nanoparticles thus present a promising vaccination approach against SARS-CoV-2 and other coronaviruses.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether there are differences in response rate and toxicity between the treatment regimen of gemcitabine combined with platinum - based drugs and other platinum - based drug combinations in the treatment of non - small - cell lung cancer (NSCLC). Specifically, by meta - analyzing clinical trial data, the researchers aimed to evaluate the efficacy and safety of gemcitabine combined with platinum - based drugs, especially comparing the performance of other platinum - based drug combinations in treatment effects (such as partial or complete response) and side effects (such as alopecia, nausea and vomiting, anemia, neutropenia, thrombocytopenia and neuropathy). The research methods included pooling the summary statistics of clinical trials published as of December 2001 using a fixed - effect model and analyzing the odds ratio (OR) and its confidence interval (CI) between different treatment regimens. The research results showed that patients receiving gemcitabine combined with platinum - based drugs had a higher response rate to treatment and less alopecia and neutropenia, but a higher incidence of anemia and thrombocytopenia. For neuropathy and nausea and vomiting, there was no evidence that any chemotherapy regimen had an advantage in reducing these side effects. The conclusion pointed out that if the main goal of treatment is to improve the response rate, then from a purely clinical perspective, gemcitabine should be the preferred treatment regimen. However, in order to verify these results, it is recommended to conduct a stratified meta - analysis based on patient - level data. This will not only help to confirm the effectiveness of gemcitabine combination therapy, but also more comprehensively evaluate its safety and tolerability in practical applications.

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses